Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics reported a significant increase in net loss for the year ended June 2025, despite making progress in clinical validation and development. The company has established a special purpose vehicle to conduct FDA trials for its HOPE® 1 product and has demonstrated the efficacy of its treatments in a study comparing them to Lyrica®. Zelira’s proprietary formulations under the HOPE® brand are generating revenue in multiple regions, and the company plans to expand its ZENIVOL® product into Germany. Additionally, Zelira is exploring commercialization opportunities for its Zyraydi™ technology and continues to generate revenue from its OTC products.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics is a global biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based medicines. The company focuses on creating clinically validated products for conditions such as insomnia, autism, and chronic noncancer pain, offering both prescription and over-the-counter products. Zelira has a portfolio of proprietary products and a pipeline of candidates for global markets.
Average Trading Volume: 3,154
Technical Sentiment Signal: Sell
Current Market Cap: A$5.12M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.